Sei Investments Co. Acquires 24,662 Shares of Repligen Co. (NASDAQ:RGEN)

Sei Investments Co. boosted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 12.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 219,604 shares of the biotechnology company’s stock after acquiring an additional 24,662 shares during the quarter. Sei Investments Co.’s holdings in Repligen were worth $31,610,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Raymond James Financial Inc. bought a new stake in shares of Repligen during the fourth quarter valued at approximately $52,492,000. Allspring Global Investments Holdings LLC lifted its holdings in Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after buying an additional 203,011 shares in the last quarter. DF Dent & Co. Inc. boosted its position in Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the last quarter. Two Sigma Advisers LP increased its stake in shares of Repligen by 421.9% in the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock valued at $18,796,000 after buying an additional 102,100 shares during the period. Finally, Fred Alger Management LLC raised its position in shares of Repligen by 29.5% during the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock worth $59,313,000 after acquiring an additional 90,831 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

RGEN stock opened at $141.95 on Wednesday. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $187.25. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.97 billion, a PE ratio of -278.33, a P/E/G ratio of 4.54 and a beta of 0.95. The business’s 50-day moving average price is $155.62 and its two-hundred day moving average price is $148.36.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. As a group, research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on RGEN shares. Canaccord Genuity Group lifted their price objective on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. StockNews.com downgraded shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Royal Bank of Canada raised their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Evercore ISI began coverage on shares of Repligen in a research report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. Finally, TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $178.64.

Insider Activity

In related news, Director Margaret Pax acquired 250 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.